Found 7 matching trials
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3This Phase 3 clinical study compares the efficacy and safety of elacestrant...
Location
The University of Arizona Cancer Center
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
PHASE3The primary goal of this study is to evaluate the effectiveness of elacestr...
Location
Southern Cancer Center, PC
Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)
PHASE2Single agent endocrine therapy (ET), with selective estrogen receptor degra...
Location
European Institute of Oncology
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
PHASE2The goal of this trial is to see if active surveillance monitoring and horm...
Location
Berkeley Outpatient Center
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
PHASE1The aim of this study is to identify the optimal dose for EP0062 as monothe...
Location
Yale School of Medicine
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
PHASE1Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+...
Status
Active Not Recruiting
Location
Research Facility
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
PHASE2The majority of patients (pts) with breast cancer have hormone receptor pos...
Status
Active Not Recruiting
Location
University of Miami